Newsroom

April 2, 2020 – Sera announced the appointment of Jay M. Moyes as Chief Financial Officer.

Feb 24, 2020 — Sera will be presenting at the upcoming Cowen 2020 Health Care Conference at the Boston Marriott Copley Place in Boston on Tuesday, March 3rd, at 11:30 a.m. ET.

Jan 28, 2020 — Sera announced two podium presentations describing the performance of the company’s technologies for predicting the individual risk of prematurity for women when prospectively tested in mid pregnancy.

Jan 9, 2020 – Sera announced the completion of the Prevent PTB clinical study conducted by Intermountain Healthcare. This study is the first of its kind to measure the impact on maternal and neonatal health and healthcare costs when standard medical interventions are used to proactively treat mothers screened at high risk for prematurity by the PreTRM® Test.

Jan 6, 2020 — Sera will be presenting at the upcoming JP Morgan 2020 Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15th, at 3:30 p.m. PT.

Nov 18, 2019 – Sera announced that a key scientific publication, “Effects of Selective Exclusion of Patients on Preterm Birth Test Performance,” authenticates Sera as the leading authority in using biomarkers to assess preterm birth risk.

Nov. 13, 2019 – Sera announced it has raised $36 million in Series D financing led by Blue Ox Healthcare Partners, an investment firm providing growth capital to healthcare companies targeting individuality and value-based care.

Nov. 1, 2019 — Sera will be presenting at the upcoming Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City on Thursday, December 5th at 12:30 p.m. ET.

Oct. 21, 2019 — Sera announced that Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will be presenting at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum at the Westin Grand Central Hotel in New York City on Thursday, November 21st, at 3:00 p.m. ET

Aug. 5, 2019 -Sera announced an initial readout of clinical data from its prospective real-time study, TREETOP, which is designed to assess the performance of the PreTRM® Test for the prediction of prematurity risk in a completely independent large cohort of pregnant women across the U.S.